Dexamethasone as a probe for docetaxel clearance

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 3, 2004, Pages 265-272

  Puisset, Florent ^a   Chatelut, Etienne ^a   Dalenc, Florence ^a   Busi, Florent ^b   Cresteil, Thierry ^b   Azéma, Joëlle ^c   Poublanc, Muriel ^a   Hennebelle, Isabelle ^a   Lafont, Thierry ^a   Chevreau, Christine ^a   Roché, Henri ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^c UPS)   (France)

Author keywords

Cytochrome P450; P glycoprotein transporter; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; OROSOMUCOID;

ADULT; AGED; ARTICLE; BAYES THEOREM; CORRELATION ANALYSIS; COVARIANCE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENOTYPE; HUMAN; HYDROXYLATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

EID: 4344599828     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0823-0     Document Type: Article

References (23)

1. Baille P, Bruno R, Schellens JH, Webster LK, Millward M, Verweij J, Montay G (1997) Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3:1535-1538
2. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195-222
3. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172
4. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDRl gene in white subjects. Clin Pharmacol Ther 69:169-174
5. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105-112
6. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
7. Gustavson L, Benet LZ (1985) Pharmacokinetics of natural and synthetic glucocorticoids. In: Anderson DC, Winter JSD (eds) Butterworth's international medical reviews in endocrinology (vol. adrenal cortex). Butterworth, London, pp 235-281
8. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478
10. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
11. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-219
12. Lamba JK, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG (2002) Common allelic variants of cytochrome P450 3A4 and their prevalence in different populations. Pharmacogenetics 12:121-132
13. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A (2003) Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 74:364-371
14. Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ, Bishop JF, Clarke SJ (2000) Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 6:3480-3485
15. Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bull A, Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 45:213-218
16. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401
17. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
18. Terasawa T, Okada T (1991) Selenium dioxide oxidation of steroidal 1,4-dien-3-ones. A simple and convenient route to 6-hydroxycorticoids. Synthetic Commun 21:307-317
19. Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14:147-151
20. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278
21. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N (2000) Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301-2308
22. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598-2603
23. van Zuylen L, Sparreboom A, van der GA, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6:1365-1371